Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma

@article{Miloevi2018PotentialOT,
  title={Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma},
  author={Zorica Milo{\vs}evi{\'c} and Jasna Bankovi{\'c} and Jelena Dini{\'c} and Chrisiida Tsimplouli and Evangelia Sereti and Miodrag D. Dragoj and Verica Paunovi{\'c} and Zorka Milovanovi{\'c} and Marija Stepanovi{\'c} and Nikola T Tani{\'c} and Kostantinos Dimas and Milica Pe{\vs}i{\'c}},
  journal={Cellular Oncology},
  year={2018},
  volume={41},
  pages={409-426}
}
PurposeAnaplastic thyroid carcinoma (ATC) is an aggressive, chemo-resistant malignancy. Chemo-resistance is often associated with changes in activity of the RAS/MAPK/ERK and PI3K/AKT/mTOR pathways and/or a high expression of ATP binding cassette (ABC) transporters, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). To assess the therapeutic efficacy in ATC of a combination of the dual mTOR kinase inhibitor vistusertib (AZD2014) and paclitaxel (PTX), we generated a new… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Rumio, The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells

F. Marcucci, C. P. Ghezzi
  • Mol. Cancer 16,
  • 2017
VIEW 1 EXCERPT

Anaplastic Thyroid Carcinoma, Version 2.2015.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2015
VIEW 1 EXCERPT